10x Genomics Inc (MEX:TXG) Stock Price, Trades & News

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	6.63
Equity-to-Asset	0.8
Debt-to-Equity	0.1
Debt-to-EBITDA	0.96
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	15.95	Distress Grey Safe
Beneish M-Score	-2.57	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	4.3
	3-Year EPS without NRI Growth Rate	23
	3-Year Book Growth Rate	-3.8
	Future 3-5Y Total Revenue Growth Rate Estimate	4.85

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	9-Day RSI	59.73
	14-Day RSI	50.65
	6-1 Month Momentum %	-7.56
	12-1 Month Momentum %	123.69

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.9
	Quick Ratio	5.42
	Cash Ratio	4.75
	Days Inventory	118.6
	Days Sales Outstanding	26.55
	Days Payable	27.91

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-3.5
	Shareholder Yield %	-0.01

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	69.6
	Operating Margin %	-12.43
	Net Margin %	-3.55
	EBITDA Margin %	13.32
	FCF Margin %	19.05
	OCF Margin %	19.93
	ROE %	-2.92
	ROA %	-2.28
	ROIC %	-17.07
	3-Year ROIIC %	-135.75
	ROC (Joel Greenblatt) %	12.48
	ROCE %	4.52
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	8.78
	PB Ratio	7.05
	Price-to-Tangible-Book	7.66
	Price-to-Free-Cash-Flow	46.02
	Price-to-Operating-Cash-Flow	43.97
	EV-to-EBIT	130.14
	EV-to-Forward-EBIT	-29
	EV-to-EBITDA	59.9
	EV-to-Revenue	7.98
	EV-to-Forward-Revenue	5.25
	EV-to-FCF	42.49
	Price-to-GF-Value	2.35
	Price-to-Net-Current-Asset-Value	12.26
	Price-to-Net-Cash	16.98
	Earnings Yield (Greenblatt) %	0.76
	FCF Yield %	2.2

Financials (Next Earnings Date:2026-08-06)

Annual Quarterly TTM

MEX:TXG's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

10x Genomics Inc Executives

Details

GF Value™: MXN142.66

MEX:TXG

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with TXG. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil MXN)	11,722.93
	EPS (TTM) (MXN)	-2.865
	Beta	-0.3612
	3-Year Sharpe Ratio	-0.22
	3-Year Sortino Ratio	-0.3
	Volatility %	78.83
	14-Day RSI	50.65
	14-Day ATR (MXN)	0.002363
	20-Day SMA (MXN)	335.54
	12-1 Month Momentum %	123.69
	52-Week Range (MXN)	150 - 363
	Shares Outstanding (Mil)	126.96

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

10x Genomics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

10x Genomics Inc Stock Events

Financials Calendars

Event	Date	Price (MXN)
Third quarter earnings conference call for 2026	2026-11-06 16:30	In 112 days
Third quarter earnings results for 2026	2026-11-06	In 111 days
Second quarter earnings conference call for 2026	2026-08-06 16:30	In 20 days
Second quarter earnings results for 2026	2026-08-06	In 19 days
General meeting for 2026	2026-06-04 11:30	335.54 (+0.00%)
Guidance call for 2026	2026-05-13 17:00	335.54 (+0.00%)
First quarter earnings conference call for 2026	2026-05-07 16:30	335.54 (+0.00%)
First quarter earnings results for 2026	2026-05-07	335.54 (+0.00%)
46th Annual TD Cowen Health Care Conference	2026-03-03 11:50	332.00 (+0.00%)
Annual report for 2025	2026-02-13	302.00 (+0.00%)

Show

Entries

10x Genomics Inc Frequently Asked Questions

What is 10x Genomics Inc(MEX:TXG)'s stock price today?

The current price of MEX:TXG is MXN335.54. The 52 week high of MEX:TXG is MXN363.00 and 52 week low is MXN150.00.

When is next earnings date of 10x Genomics Inc(MEX:TXG)?

The next earnings date of 10x Genomics Inc(MEX:TXG) is 2026-08-06.

Does 10x Genomics Inc(MEX:TXG) pay dividends? If so, how much?

10x Genomics Inc(MEX:TXG) does not pay dividend.

Press Release

	Subject	Date
	10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026	2026-07-15
	10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer	2026-06-17
	10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group	2026-06-09
	10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference	2026-04-29
	10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood	2026-04-18
	10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026	2026-04-15
	Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs	2026-03-25
	PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas	2026-03-17
	10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference	2026-02-19
	10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026	2026-02-12

10/Page

Articles on 10x Genomics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.